Lipocine Inc (LPCN)

Lipocine Inc. is a clinical-stage biopharmaceutical company focused on researching and developing drug-delivery technologies and oral therapies. The company markets TLANDO, an oral testosterone replacement therapy based on testosterone undecanoate, and is advancing a pipeline that includes LPCN 1154 (BRLIZIO) for postpartum depression, LPCN 1148 for decompensated cirrhosis, LPCN 1107 for prevention of recurrent preterm birth, LPCN 1144 for pre-cirrhotic non-alcoholic steatohepatitis, and LPCN 2401 for obesity management. Additional development programs include LPCN 2201 for major depressive disorders, LPCN 2203 for essential tremor, and LPCN 2101 for drug-resistant epilepsy and epilepsy in women. Lipocine also collaborates with Verity Pharmaceuticals on TLANDO and TLANDO XR, a once-daily testosterone replacement candidate. The company focuses on therapeutic areas including central nervous system disorders, liver disease, and hormone supplementation in the United States.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.